NCT05336201 Cognitive Remediation Intervention to Prepare for Transition of Care
| NCT ID | NCT05336201 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University of Alabama at Birmingham |
| Condition | Sickle Cell Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2022-07-01 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 120 participants in total. It began in 2022-07-01 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Randomized Controlled Trial (RTC) testing the efficacy of a telehealth adaptation of the Cognitive-Remediation of Executive and Adaptive Deficits in Youth (C-READY) intervention to prepare adolescents with sickle cell disease for transition of care.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of SCD (all genotypes) * Active follow-up at Children's of Alabama Hospital * Ages 10-18 * English-speaking Exclusion Criteria: * History of seizures or overt stroke * History of Intellectual Disability or Autism Spectrum Disorder * Inability to participate in the MRI scan, such as metal implants, neurostimulators, claustrophobia * Currently on psychotropic medications
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05336201 clinical trial?
This trial is open to participants of all sexes, aged 10 Years or older, up to 18 Years, studying Sickle Cell Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05336201 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT05336201 currently recruiting?
Yes, NCT05336201 is actively recruiting participants. Contact the research team at donnamurdaugh@uabmc.edu for enrollment information.
Where is the NCT05336201 trial being conducted?
This trial is being conducted at Birmingham, United States.
Who is sponsoring the NCT05336201 clinical trial?
NCT05336201 is sponsored by University of Alabama at Birmingham. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.